2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2495 High-sensitivity plasma cell-free DNA (cfDNA) versus bone marrow next-generation sequencing (NGS) for molecular monitoring after allogeneic hematopoietic cell transplantation (allo-HCT)

Tuan Le Phan, MD, Ann-Kathrin Eisfeld, MD2, Hannah Choe, MD3, Nathan Denlinger, DO, MS4, Polina Shindiapina, MD, PhD5, Sarah Wall, MD,MPH6, Roberta C. G. Azbell, MD7, Marcos De lima, MD8, Sumithira Vasu, MBBS., MD9, Jiasheng Wang, MD10
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
10 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Background: Relapse remains a major cause of treatment failure after allogeneic hematopoietic cell transplantation (allo-HCT), creating a need for sensitive and minimally invasive molecular surveillance. Although bone marrow (BM) is routinely used for post-transplant disease assessment, its collection is invasive and may limit frequent serial monitoring. Plasma cell-free DNA (cfDNA) can be obtained serially from peripheral blood (PB) providing information complementary to BM specimens. However, its interpretation is complicated by variants arising from residual leukemia, recipient or donor clonal hematopoiesis, and nonhematopoietic sites. Therefore, we compared paired cfDNA and BM next generation sequencing (NGS) findings and examined the relationship between cfDNA-detected mutations and subsequent relapse.

Methods: Plasma cfDNA was analyzed using a targeted 302-gene NGS panel (Genomic Testing Cooperative – Liquid Trace) with reported limits of detection of 0.1% VAF for hotspot mutations, 0.5% for single-nucleotide variants (SNVs), and 1% for small insertions or deletions (indels). BM DNA was analyzed using a 50-gene AmpliSeq panel, with detection limits of 1%–2% VAF for commonly mutated sites, 5% for other SNVs, and 5%–10% for indels. Comparisons were restricted to the 50 genes shared by both assays. cfDNA and BM specimens were considered paired when collected within 30 days of each other.

Results: We retrospectively reviewed 46 paired plasma cfDNA and bone marrow samples from 39 allo-HCT recipients (HLA-matched donors: n=27, haplo-identical/mismatched donors: n=12), including 29 patients with AML, 8 with MDS, 1 with ALL, and 1 with aplastic anemia. Myeloablative conditioning was used in 11 patients and the remaining 28 patients received reduced intensity conditioning. GVHD prophylaxis was post-transplant cyclophosphamide (PTCY)-based for 27 patients and calcineurin inhibitor-based for 12 patients. Median age of the cohort at latest follow-up was 57.5 years (range 24-72). Samples were collected a median of 54 days after allo-HCT (IQR, 29–101). cfDNA detected at least one somatic variant in 24 of 46 samples (52.2%), representing 22 of 39 (56.4%) patients. Total 48 cfDNA variants were reported and had a median variant allele frequency (VAF) of 0.52% (IQR, 0.32–0.98%), and 36 (75.0%) were below 1%. Of these, 6 variants (12.5%) were also detected in paired bone marrow (BM), including DNMT3A, NRAS, and SRSF2, whereas cfDNA identified 42 additional variants not detected in BM. Conversely, BM identified 2 variants absent from cfDNA: STAG2 and CSF3R. Mutations in the traditional DTA clonal hematopoiesis genes, DNMT3A, TET2, and ASXL1, accounted for 21 of 48 cfDNA variants (43.8%) and were the sole findings in 8 of 24 positive samples (33.3%). Sixteen patients had at least one additional non-DTA variant, including STAG2, SRSF2, TP53, NRAS, RUNX1, PTPN11, IDH2, CBL, U2AF1, and NOTCH1.

At a median follow-up of 9.2 months after HCT, 6 of 39 patients (15.4%) had relapsed. Five of these patients underwent cfDNA testing before relapse, at a median of 76 days before diagnosis (range, 43–143 days). cfDNA detected high-risk driver mutations in 2 patients: TP53 E298* at VAF 0.60% and ABL1 T315I at VAF 0.46%, identified 56 and 83 days before relapse, respectively. Neither mutation was detected in the paired BM. The other 3 patients had negative results.

Conclusions: The high-sensitivity plasma cfDNA assay expanded detection of low-VAF variants beyond paired BM NGS, including cfDNA-only mutations that preceded relapse. cfDNA frequently detected clonal hematopoiesis-associated variants, but their clinical significance in allo-HCT surveillance remains uncertain. Earlier detection of these mutations may provide a therapeutic window to initiate maintenance or decisions about immunomodulation post allo-HCT. Larger studies incorporating serial sampling and relapse correlation are needed to determine whether cfDNA can reliably complement or potentially replace BM for post-HCT disease monitoring.

Tuan Le Phan, MD: No relevant conflicts of interest to declare.